Lifeworks Advisors LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lifeworks Advisors LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 32.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,909 shares of the biopharmaceutical company's stock after acquiring an additional 2,166 shares during the period. Regeneron Pharmaceuticals makes up approximately 0.9% of Lifeworks Advisors LLC's investment portfolio, making the stock its 29th largest position. Lifeworks Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $5,650,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. TD Private Client Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares during the last quarter. Adirondack Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after acquiring an additional 18 shares during the last quarter. Prestige Wealth Management Group LLC lifted its holdings in Regeneron Pharmaceuticals by 23.2% in the fourth quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 19 shares during the last quarter. Kingswood Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after acquiring an additional 19 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV lifted its holdings in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after acquiring an additional 19 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on REGN shares. UBS Group boosted their target price on Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the company a "neutral" rating in a research report on Friday, July 11th. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Truist Financial cut their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $837.61.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $1.54 on Friday, reaching $563.10. The company's stock had a trading volume of 755,785 shares, compared to its average volume of 906,903. The stock's 50-day moving average is $542.56 and its two-hundred day moving average is $609.57. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock has a market capitalization of $60.79 billion, a P/E ratio of 14.34, a PEG ratio of 2.11 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the previous year, the company posted $9.55 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.